New Hot Topic: Axumin™ (Fluciclovine F 18) Injection for PET Imaging of Recurrent Prostate Cancer -

In this 5 for 5 Hot Topics, Phillip Koo, MD. presents the clinical background of Axumin™ (Fluciclovine F 18) Injection for PET Imaging of Recurrent Prostate Cancer, the first FDA-approved F18 PET Imaging Agent indicated in for use in patients with suspected recurrent prostate cancer.  Dr. Koo discusses its use for men with suspected prostate cancer recurrence based on elevated PSA levels following prior treatment. The products safety, efficacy, and good inter-reader variability, as well as the adverse reactions including injection site pain, redness, and a metallic taste in the mouth.


Phillip Koo, MD.
Associate Professor, Radiology - Nuclear Medicine
University of Colorado School of Medicine
Aurora, Colorado

Dr. Koo is the associate professor of radiology, nuclear medicine at the University of Colorado School of Medicine. He is a graduate of Drexel University College of Medicine and is a Fellow at the Brigham and Women's Hospital/Children's Hospital/Harvard Medical School Program. A member of the American College of Radiology (ACR), Radiological Society of North America (RSNA), and Society of Nuclear Medicine (SNM), Dr. Koo has also been recognized as a "Top Doctor" the past three years (2013 - 2015) in 5280 Magazine, a local magazine for and about the Denver area. In addition, Dr. Koo was the recipient of the Ursula Mary Kocemba-Slosky Award, SNMMI/ERF, in 2015, which represents the Society of Nuclear Medicine and Medical Imaging's commitment to advancing molecular imaging and therapy by supporting the next generation of researchers. 


For More information of F18:

Read about the FDA Approval of Axumin™

Read More on Fluciclovine F 18: Clin Nucl Med. 2015 Aug;40(8):e386-91. doi: 10.1097/RLU.0000000000000849.